COMP <GO>
LQDA vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Liquidia Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LQDA 4
— ABBV 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LQDA
LAST: $45.06 (+0.16%) • MKT CAP: $4.03B
balance-sheet
6.33
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LQDA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LQDA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.60% | 29.00% | -41.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.99% | 3.47% | -4.46 | ABBV | /fcf-yield <GO> |
| Operating Margin | -32.50% | 24.60% | -57.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -43.50% | 6.90% | -50.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.60% | +171.40 | LQDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 6.33 | 5.33 | +1.00 | LQDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | LQDA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 72.8 | -20.25 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.15 | -0.25 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 113.1x | -92.10 | LQDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $513.86B | -$509.83B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LQDA REV | ABBV REV | LQDA GROSS % | ABBV GROSS % | LQDA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $158.3M | $61.16B | 44.0% | 70.2% | -$40.0M | $17.82B |
| FY 2024 | $14.0M | $56.33B | 58.0% | 70.0% | -$98.4M | $17.83B |
| FY 2023 | $17.5M | $54.32B | 44.0% | 44.0% | -$42.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LQDA // BETA 0.90
ABBV // BETA 1.15